On July 15, UPS revealed the name of Angela Hwang as new member to have joined the Board’s Audit Committee. Her appointment brings the total number of directors at the Board to 13.
Hwang, age 54, is a member of Pfizer’s Executive Team and is Group President of the Pfizer Bio pharmaceuticals Group, which comprises approximately 80% of Pfizer’s revenues. In this role, she leads more than 26,000 global colleagues and has responsibility for bringing over 600 innovative medicines and products to patients around the world.
Hwang oversees seven commercial business units, which in 2019 generated nearly $40 billion in revenues, and impacted the lives of over 434 million patients across 125 countries. Together, these businesses strive to deliver transformational medicines that address major global health priorities in cancer, rare disease, inflammation & immunology, primary care, infectious diseases, and preventative care with vaccines.
“The UPS Board engaged in a thorough search and evaluation to find the right candidate for this role,” said UPS Executive Chairman of the Board David Abney. “Angela’s expertise in the healthcare sector will bring added talent to our Board as we oversee the company’s strategic growth efforts in this area.”
“Angela is an outstanding, proven leader who brings added healthcare and global management experience to our Board,” said UPS Chief Executive Officer Carol Tomé. “We couldn’t be more thrilled to welcome Angela to the UPS Board of Directors during this time when UPS continues to expand its leadership in the healthcare logistics space, launching new healthcare services for UPS customers.”
Hwang is a 23-year veteran of Pfizer, and has held numerous leadership roles within the company. Prior to leading the Pfizer Biopharmaceuticals Group, she held more than 10 different positions in the company, spanning strategy, product development, marketing, sales, and general management. She is known as a transformational leader who drives for innovation and outstanding business performance and her experience covers a wide array of therapeutic areas and medicines in all lifecycle stages, as well as geographical breadth in both developed and emerging markets.
Hwang also sits on the boards of European Federation of Pharmaceutical Industries and Associations (EFPIA), as well as the Pfizer Foundation, a charitable organisation that addresses global health challenges. She has been active in industry groups such as the Biotechnology Innovation Organisation (BIO), where she previously co-chaired the Vaccines Policy Committee.
In 2019, she was also named to Crain’s Notable Women in Healthcare list.
